Analysts Anticipate $56.86 Price Target as Bristol Myers Squibb Raises EPS Guidance to $6.60
Analysts set a consensus “Hold” rating (1 sell, 13 hold, 7 buy) on BMY with an average 12-month price target of $56.86. Bristol Myers declared a $0.63 quarterly dividend (4.6% yield), raised FY2025 EPS guidance to $6.40–$6.60, and reported Q3 revenue of $12.22B (+2.8%) with EPS of $1.63.
1. Analyst Consensus Holds Steady
Twenty-one brokerage firms currently cover Bristol Myers Squibb, assigning a consensus recommendation of Hold. Within that group, one analyst rates the shares as Sell, thirteen maintain Hold ratings and seven remain Bullish. Over the past twelve months, these analysts have published an average one-year target of approximately fifty-seven dollars per share, reflecting tempered growth expectations as the company navigates patent expirations on several legacy oncology products.
2. Divergent Broker Views
Research houses have offered varied perspectives in recent months. Weiss Ratings reiterated its hold (C-) assessment in mid-October, while HSBC reaffirmed its neutral stance and set an unchanged objective in early December. In contrast, Wall Street Zen upgraded its outlook from Buy to Strong Buy in November, citing positive Phase III readouts for an investigational immunology agent. Morgan Stanley, meanwhile, maintained an Underweight rating but edged its price objective slightly higher, and DBS Bank adopted a Moderate Buy position following stronger than expected clinical data in hematology.
3. Hedge Fund Activity Signals Confidence
Institutional investors control roughly three-quarters of Bristol Myers Squibb’s outstanding shares. During the second quarter, Trifecta Capital Advisors and Darwin Wealth Management each initiated stakes valued near twenty-five thousand dollars, while REAP Financial Group more than tripled its position to nearly six hundred shares. In the third quarter, Harbor Capital Advisors boosted its holding by just over 100 percent and Kerr Financial Planning established a new stake. These shifts suggest selective accumulation ahead of upcoming regulatory decisions.
4. Solid Q3 Results and Enhanced Payout
In late October the company reported third-quarter revenue of $12.22 billion, up 2.8 percent year-over-year, and delivered earnings per share of $1.63, beating consensus by eleven cents. Management reaffirmed full-year guidance of 6.40 to 6.60 EPS. Shortly thereafter, the board approved a quarterly dividend increase to $0.63 per share, representing a 1.6 percent raise and an annualized yield near 4.6 percent. This marks the fifteenth consecutive year of dividend growth, underlining commitment to shareholder returns.